AlertEdge.io
Single-Ticker Trade Brief
DOC — Healthpeak Properties Report Date: 2026-10-22 20:38 UTC  |  Sector: Real Estate  |  Rating:
RISK DISCLAIMER: This is an automated breakout signal. Always validate before entering a position.
▲ Breakout Signal — Volume Confirmed

DOC closed above the $19.06 breakout level on 1.57x average volume. ATR-based levels set automatically. Next resistance target: $20.12.

Ticker
DOC
Entry Price
$19.34
Breakout Level
$19.06
Stop Loss
$18.67
TP1 Target
$20.12
TP2 Target
$20.64
Risk / Reward
1 : 1.16
1.57x avg volume
View DOC Chart on TradingView

Key Price Levels

TP1 Target
$20.12
Breakout Level
$19.06
Entry
$19.34
Stop Loss
$18.67

Fundamentals

P/E Ratio
55.257145
EPS (TTM)
0.35
Dividend Yield
660.0%
52-Wk High
22.95
52-Wk Low
15.7
Beta
0.988

Deep Dive Analysis — Claude Sonnet

DOC — Healthpeak Properties | Trade Brief

SETUP

DOC gapped up 4.6% today, clearing the $19.06 breakout level on 1.57x average volume. The bar closed near its high, showing buyers in control and minimal selling pressure into the close. Price is now working toward filling the gap down from the $22.95 52-week high range. The move is extended intraday, so entry here is chasing a bit, which the 50/100 signal score reflects. Risk/reward of 1:1.16 is thin for a REIT with this much noise in earnings history.

CATALYSTS

The April 2025 earnings beat of 13.5% followed a bounce-back quarter after a brutal February miss. The earnings pattern is erratic but the most recent print was constructive. Broad tailwinds in healthcare real estate, particularly life sciences and medical outpatient buildings, remain intact as aging demographics drive demand. Rate-cut expectations from the Fed are a meaningful macro tailwind for REITs broadly, reducing cap rate pressure and improving acquisition economics.

RISKS

Earnings consistency is a real problem here. Two significant misses in the past five quarters suggest FFO visibility is low and guidance credibility is shaky. The P/E of 55x on $0.35 EPS is stretched for a REIT where FFO matters more than net income, and the 660% dividend figure is almost certainly a data anomaly worth verifying before sizing in. The 52-week high sits at $22.95, meaning there is overhead resistance before targets are even tested. A reversal of today's gap with no news catalyst behind it would be a red flag. Stop at $18.67 is tight and could be clipped on any intraday pullback.

Insider activity is a mild positive. Multiple executives bought shares in late May at prices near current levels, suggesting internal confidence, though the share amounts are small, likely routine compensation-related purchases.

CONVICTION: Low

The risk/reward is barely above 1:1, earnings history is unreliable, no news catalyst explains the gap, and the signal quality score flags this as a technically extended entry with limited edge.